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Programmed death 1 (PD-1; CD279), also known as programmed cell death protein 1 
(PDCD-1), is a cell surface receptor of the immunoglobulin superfamily found on immune 
effector cells. It belongs to the extended CD28/CTLA-4 family of T-cell regulators and is 
expressed by a range of immune cells, including B cells, natural killer cells, and monocytes. 
Binding of PD-1 to one of its ligands, PD ligand 1 (PD-L1) or PD-L2, on antigen-presenting 
cells (APCs) is known to negatively regulate T-cell receptor signaling and inhibit T-cell 
activation [1]. In this issue of the Journal, Singh et al [2] demonstrate that the coinhibitory 
receptor PD-1 and the PD ligands are expressed on higher percentages of peripheral blood 
mononuclear cells (PBMCs) of patients with active tuberculosis than those of healthy 
controls in an area of tuberculosis endemicity. The expression of PD-1 on T cells is 
upregulated following in vitro stimulation with Mycobacterium tuberculosis antigens, and 
the PD-1 blockade in vitro enhances interferon γ (IFN-γ) and interleukin 2 production by 
specific T cells and rescues them from undergoing apoptosis. Of particular significance, the 
authors demonstrate during a 1-year follow-up period a significant decrease in the frequency 
of PD-1–expressing T cells after successful antituberculosis treatment that led to restoration 
of the M. tuberculosis–specific T-cell cytokine response in vitro. These data substantiate the 
role of PD-1–PD-L pathways in the inhibition of T-cell responses in patients with active 
tuberculosis.
Optimal T-cell activation during infection requires 2 signals. The first signal is generated by 
T-cell–receptor recognition of peptide–major histocompatibility complex presented by an 
APC, while the second signal is provided by binding of costimulatory receptor CD28 on the 
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T-cell surface with one of the classic B7 family members (CD80 or CD86) on the APC. 
However, the persistent immune activation that is typical of chronic viral infections is 
marked by increased expression and signaling through the inhibitory receptors like PD-1 and 
results in exhaustion and dysfunction of T cells [3, 4]. Pulmonary tuberculosis is usually a 
chronic lung disease, and both CD4+ and CD8+ T-cell responses play an important part in 
protection against M. tuberculosis infection. Previously, PD-1 expression on the PBMCs, 
pleural fluid mononuclear cells [5], and natural killer cells [6] was shown to be upregulated 
following in vitro antigen stimulation in patients with tuberculosis, suggesting that this 
upregulation may be one of the potential mechanisms of impaired innate and adaptive 
immune responses in active tuberculosis. Studies performed to date using a PD-1 knockout 
mouse strain or passive transfer of PD-1–expressing M. tuberculosis–specific T cells in mice 
did not conclusively demonstrate the possible role of PD-1 in T-cell exhaustion or 
dysfunction in chronic M. tuberculosis infection [7–9]. It has been suggested that a number 
of pathogens induce immune evasion by upregulating PD-1 or its ligands, and the blockade 
of the PD-1/PD-L pathway in most of these models enhances immune functions for the 
benefit of the host. This concept led to the expectation that PD-1–deficient mice might elicit 
sterilizing immune response against M. tuberculosis after challenge. Unexpectedly, PD-1–
deficient mice showed extreme sensitivity to M. tuberculosis aerosol infection, with reduced 
survival and a higher bacillary burden in the lungs [7]. This effect was associated with 
profoundly upregulated inflammatory responses in the lungs, with focal necrotic areas 
showing neutrophilic infiltrates, suggesting that the PD-1 pathway is required to control 
excessive inflammatory responses after M. tuberculosis infection. Adoptive transfer studies 
of M. tuberculosis–specific CD4+ T cells from PD-1 knockout mice further demonstrated 
that the CD4+ T cells promote M. tuberculosis infection in the absence of normal PD-1 
inhibition [9]. The observation of increased M. tuberculosis susceptibility in PD-1 knockout 
mice led to the suggestion that PD-1 does not play an inhibitory role during M. tuberculosis 
infection but instead promotes M. tuberculosis clearance [8]. Next, a study evaluating the 
role of PD-1 in CD4+ T-cell exhaustion in the mouse model of tuberculosis suggested that 
the PD-1 expression identifies a population of activated effector T cells, and PD-1–
expressing cells transition into terminally differentiated killer cell lectin-like receptor 
subfamily G member 1 (KLRG1)–expressing effector cells [10]. This led to the conclusion 
that PD-1 and KLRG1 identify differentiating, but not exhausted, CD4+ T cells in M. 
tuberculosis–infected mice during the 1-year follow-up period after infection [10].
The current study by Singh et al [2] demonstrates the numeric dominance of inhibitory PD-1 
receptor– and ligand(s)–expressing T cells, CD19+ B cells, and CD14+ monocytes or 
macrophages in the PBMCs of patients with pulmonary tuberculosis, compared to that in 
healthy controls. The study shows that the PD-1–PD-L1/L2 pathways are actively involved 
in inhibiting cytokine production and proliferation of M. tuberculosis–specific T cells. The 
majority of patients with tuberculosis used in their study had moderate or far-advanced 
disease, and the authors show that the frequencies of PD-1+ T cells and per-cell expression 
of PD-1 receptors significantly correlate with the bacillary load in the sputum of patients 
with newly diagnosed tuberculosis. Although the results of the study by Singh et al that 
describe the immune-inhibitory role of PD-1 in the pathogenesis of human tuberculosis 
appear paradoxical in the context of previously published observations describing reduced 
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survival of PD-1 knockout mice after M. tuberculosis challenge, together these results offer 
a more complete picture regarding the role of PD-1 in human M. tuberculosis infection and 
disease. It is possible that the M. tuberculosis infection may upregulate expression of PD-1 
ligands on APCs, and presentation of M. tuberculosis antigens by APCs may lead to 
production of IFN-γ by T cells, which in turn may upregulate PD-1 expression on T cells. 
The authors propose that the basal level of PD-1 expression might play a homeostatic role in 
shaping T-cell responses during early M. tuberculosis infection in humans and help control 
the excessive inflammatory response. However, the persistent antigen stimulation during 
chronic M. tuberculosis infection may promote overexpression of PD-1 on T cells, leading to 
dysfunction or exhaustion.
Although 50% of healthy controls investigated by Singh et al were tuberculin skin test 
positive, M. tuberculosis infection in these donors was not confirmed. Therefore, it was not 
possible to determine the level of PD-1 expression on the T cells of infected versus 
noninfected BCG-vaccinated healthy controls and how it compares with that of patients with 
active tuberculosis in this study. It was previously shown that individuals with latent M. 
tuberculosis infection harbor high frequencies of late-stage, differentiated, antigen-specific, 
PD-1–expressing effector memory CD4+ T cells, while uninfected BCG-vaccinated 
individuals have primarily early stage cells with low PD-1 expression [11], where PD-1 
expression was evaluated after in vitro stimulation of PBMCs with M. tuberculosis antigens. 
In individuals with latent M. tuberculosis infection, PD-1–expressing antigen-specific CD4+ 
T-cell subsets produced cytokines and were polyfunctional, suggesting that these T cells 
were not exhausted. The authors of the study [11] speculated that PD-1 levels on antigen-
specific effector memory CD4+ T cells may identify individuals whose infection is at the 
higher end of the proposed spectrum of latency and are at the greatest risk of developing 
active disease. Confirmation of this thesis would require longitudinal tracking of CD4+ T-
cell responses and PD-1 expression in a nonhuman-primate model of M. tuberculosis 
infection studying the transition from latent infection to active disease. Use of 4-color flow 
cytometry by Singh et al also limited the characterization of the different APC subsets 
investigated, and simultaneous expression of PD-1 and other markers of exhaustion or 
terminal differentiation on different T-cell subsets were not studied. In the absence of M. 
tuberculosis–specific tetramers or “touch markers,” it was not possible to investigate PD-1 
expression on M. tuberculosis–specific T cells in patients with tuberculosis and controls. 
Nevertheless, this study [2] shows that the frequency of PD-1–expressing cells is increased 
during active tuberculosis and declines in PBMCs during successful antituberculosis therapy.
These results may form the basis of further evaluation of PD-1 as a possible biomarker to 
monitor the success of antituberculosis therapy in active disease, along with other markers of 
T-cell exhaustion. It will be interesting to evaluate PD-1 expression at the site of infection 
and whether PD-1 expression increases in patients with treatment failure and relapse. 
Targeting PD-1 pathways by using in vivo blockade has been shown to improve antiviral 
immune responses in animal models [12], but there have been concerns that it would also 
lead to increased inflammation and immunopathology. It was recently shown that PD-1 
blockade actually reduces proinflammatory responses and improves immunity in simian 
immunodeficiency virus (SIV)–infected macaques, suggesting that this effect might have 
therapeutic potential in chronic infections [13]. However, caution is warranted while 
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considering it in cases of coinfection with M. tuberculosis. While PD-1 blockade may hold 
therapeutic potential in patients with advanced tuberculosis, it may potentially exacerbate T-
cell activation in an already persistent inflammatory setting in latent tuberculosis, potentially 
leading to accelerated disease progression. Further studies in the nonhuman-primate model 
of tuberculosis may help decipher the therapeutic potential and alleviate some of these 
concerns. Recently, PD-1 was also found to be transiently expressed on M-72–specific CD4+ 
T cells following vaccination of healthy adults [14], and it will be interesting to see whether 
it positively or adversely affects the protective efficacy of M-72/AS01 vaccine in human 
clinical trials. Overall, the results of Singh et al substantiate an inhibitory role of PD-1 in 
patients with active tuberculosis and, together with previously published studies, underscore 
the importance of a complex balance between proinflammatory and antiinflammatory host 
factors in the control of M. tuberculosis infection.
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